Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 74,701
  • Shares Outstanding, K 47,885
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,600 K
  • 60-Month Beta -0.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.95
Trade GNPX with:

Options Overview Details

View History
  • Implied Volatility 149.38% ( +6.01%)
  • Historical Volatility 76.51%
  • IV Percentile 64%
  • IV Rank 18.94%
  • IV High 513.17% on 12/06/21
  • IV Low 64.39% on 07/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 145
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 19,749
  • Open Int (30-Day) 19,201

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.09
  • Number of Estimates 1
  • High Estimate -0.09
  • Low Estimate -0.09
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2598 +17.48%
on 05/12/22
1.9800 -25.25%
on 04/20/22
-0.3500 (-19.13%)
since 04/18/22
3-Month
1.2598 +17.48%
on 05/12/22
2.4900 -40.56%
on 03/21/22
-0.7300 (-33.03%)
since 02/18/22
52-Week
1.1700 +26.50%
on 12/30/21
4.0700 -63.64%
on 06/07/21
-2.0600 (-58.19%)
since 05/18/21

Most Recent Stories

More News
Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-2 Clinical Trial of REQORSA™ Immunogene Therapy in Combination With Keytruda® to Treat Non-Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
Genprex to Participate in Upcoming Investor Conference in March

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
Genprex to Present at Upcoming Investor Conferences Highlighting its Gene Therapies for Cancer and Diabetes

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
Preclinical Data Show Potential for Use of Genprex’s ONCOPREX® Nanoparticle Delivery System in Treating Colon Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
Genprex to Accelerate Opening of Acclaim-1 Clinical Trial Sites for REQORSA™ Systemic Gene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
Genprex to Participate in January Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
Genprex's (GNPX) Lead Cancer Drug Gets Second Fast Track Tag

The FDA bestows a Fast Track designation to Genprex's (GNPX) Reqorsa in combination with Keytruda for treating patients with non-small cell lung cancer. This is the second Fast Track tag for Reqorsa.

AZN : 63.31 (-3.55%)
MRK : 92.15 (-0.91%)
VTVT : 0.4319 (-1.84%)
GNPX : 1.4600 (-6.41%)
Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced...

GNPX : 1.4600 (-6.41%)
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) CEO to Present in CEO Roadshow Webinar

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that the company’s president and chief...

GNPX : 1.4600 (-6.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

3rd Resistance Point 1.7167
2nd Resistance Point 1.6533
1st Resistance Point 1.6067
Last Price 1.4600
1st Support Level 1.4967
2nd Support Level 1.4333
3rd Support Level 1.3867

See More

52-Week High 4.0700
Fibonacci 61.8% 2.9622
Fibonacci 50% 2.6200
Fibonacci 38.2% 2.2778
Last Price 1.4600
52-Week Low 1.1700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar